Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A clinical trial found no difference in outcomes based on whether participants switching to Cabenuva first took oral meds for four weeks.
A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
Researchers polled people on HIV treatment about their preferences for various forms of long-acting antiretrovirals.
A look at some science-based facts about HIV that may surprise you as we mark the 35th anniversary of the start of the AIDS epidemic.
Long-acting antiretroviral shots could replace oral treatments for the virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.